Abstract
This review discusses the rationale behind recommending immunopharmacological guidance of long-term therapies with anti-TNF-α specific biotherapies. “Arguments why therapeutic decision-making should not rely on clinical outcomes alone are presented. Central to this is that the use of theranostics (i.e., monitoring circulating levels of functional anti-TNF-α drugs and antidrug antibodies) would markedly improve treatment because therapies can be tailored to individual patients and provide more effective and economical long-term clinical benefits while minimising risk of side effects. Large-scale immunopharmacological knowledge of the pharmacokinetics of TNF-α biopharmaceuticals in individual patients would also help industry to develop more effective and safer TNF-α inhibitors” [1].
Original language | English |
---|---|
Pages (from-to) | 1049-1055 |
Number of pages | 7 |
Journal | Current Drug Targets |
Volume | 15 |
Issue number | 11 |
Publication status | Published - 1 Jan 2014 |
Keywords
- Anti TNF treatment
- Antibodies to anti TNF
- Crohn’s disease
- Optimisation
- Trough levels of anti TNF
- Ulcerative colitis